A combination of two therapies, azacitidine and venetoclax, or aza-ven, outperformed intensive chemotherapy for acute myeloid leukemia in patients healthy enough to receive aggressive treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback